Nathan Singh, MD, MS
- Email: firstname.lastname@example.org
Washington University in St. Louis (WU)
Our laboratory is interested in understanding the molecular pathways that regulate the success and failure of engineered T cell therapies for cancer. Through investigation of the interactions between chimeric antigen receptor (CAR) T cells and blood cancer cells, we aim to define the molecular events that permit successful target cell clearance, or alternatively lead to the development of T cell dysfunction.